Workflow
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Intellia TherapeuticsIntellia Therapeutics(US:NTLA) GlobeNewswire News Roomยท2025-07-31 23:13

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Intellia Therapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during a specific class period [1][2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Intellia who purchased shares between July 30, 2024, and January 8, 2025 [1]. - A class action complaint was filed on February 11, 2025, concerning the company's disclosures related to its NTLA-3001 study for treating AATD-associated lung disease [2]. Group 2: Company Developments - Intellia's management announced a halt to all NTLA-3001 research and a workforce reduction of 27% in 2025, indicating a strategic shift in resource allocation [3]. - The decision to discontinue NTLA-3001 was attributed to a decline in demand for viral-based editing methods, as non-viral delivery methods gained preference in the scientific community [2][3]. Group 3: Market Reaction - Following the announcement of the reorganization and discontinuation of NTLA-3001, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to $10.20 per share on January 10, 2025 [4].